FULC Long Call Strategy
FULC (Fulcrum Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC (Fulcrum Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $205.6M, a beta of 2.92 versus the broader market, a 52-week range of 2.83-15.74, average daily share volume of 2.3M, a public-listing history dating back to 2019, approximately 45 full-time employees. These structural characteristics shape how FULC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.92 indicates FULC has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on FULC?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current FULC snapshot
As of June 30, 2026, spot at $3.80, ATM IV 206.20%, IV rank 40.03%, expected move 59.12%. The long call on FULC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on FULC specifically: FULC IV at 206.20% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 59.12% (roughly $2.25 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated FULC expiries trade a higher absolute premium for lower per-day decay. Position sizing on FULC should anchor to the underlying notional of $3.80 per share and to the trader's directional view on FULC stock.
FULC long call setup
The FULC long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With FULC near $3.80, the first option leg uses a $3.80 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed FULC chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 FULC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.80 | N/A |
FULC long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
FULC long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on FULC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on FULC
Long calls on FULC express a bullish thesis with defined risk; traders use them ahead of FULC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
FULC thesis for this long call
The market-implied 1-standard-deviation range for FULC extends from approximately $1.55 on the downside to $6.05 on the upside. A FULC long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current FULC IV rank near 40.03% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on FULC should anchor more to the directional view and the expected-move geometry. As a Healthcare name, FULC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to FULC-specific events.
FULC long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. FULC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move FULC alongside the broader basket even when FULC-specific fundamentals are unchanged. Long-premium structures like a long call on FULC are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current FULC chain quotes before placing a trade.
Frequently asked questions
- What is a long call on FULC?
- A long call on FULC is the long call strategy applied to FULC (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With FULC stock trading near $3.80, the strikes shown on this page are snapped to the nearest listed FULC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are FULC long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the FULC long call priced from the end-of-day chain at a 30-day expiry (ATM IV 206.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a FULC long call?
- The breakeven for the FULC long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current FULC market-implied 1-standard-deviation expected move is approximately 59.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on FULC?
- Long calls on FULC express a bullish thesis with defined risk; traders use them ahead of FULC catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current FULC implied volatility affect this long call?
- FULC ATM IV is at 206.20% with IV rank near 40.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.